MDT

89.59

+1.05%↑

VEEV

282.21

+1.4%↑

A

114.34

-0.71%↓

WBA

11.48

-0.26%↓

HQY

97.6

-1.17%↓

MDT

89.59

+1.05%↑

VEEV

282.21

+1.4%↑

A

114.34

-0.71%↓

WBA

11.48

-0.26%↓

HQY

97.6

-1.17%↓

MDT

89.59

+1.05%↑

VEEV

282.21

+1.4%↑

A

114.34

-0.71%↓

WBA

11.48

-0.26%↓

HQY

97.6

-1.17%↓

MDT

89.59

+1.05%↑

VEEV

282.21

+1.4%↑

A

114.34

-0.71%↓

WBA

11.48

-0.26%↓

HQY

97.6

-1.17%↓

MDT

89.59

+1.05%↑

VEEV

282.21

+1.4%↑

A

114.34

-0.71%↓

WBA

11.48

-0.26%↓

HQY

97.6

-1.17%↓

Erasca Inc

Отворен

1.48 2.07

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.44

Максимум

1.6

Ключови измерители

By Trading Economics

Приходи

1.3M

-31M

Служители

103

EBITDA

-750K

-36M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+200.69% upside

Дивиденти

By Dow Jones

Следващи печалби

8.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

20M

414M

Предишно отваряне

-0.59

Предишно затваряне

1.48

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Erasca Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.07.2025 г., 23:34 ч. UTC

Придобивния, сливания и поглъщания

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17.07.2025 г., 21:14 ч. UTC

Придобивния, сливания и поглъщания

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17.07.2025 г., 21:04 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17.07.2025 г., 23:43 ч. UTC

Пазарно говорене

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17.07.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17.07.2025 г., 22:47 ч. UTC

Придобивния, сливания и поглъщания

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17.07.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17.07.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17.07.2025 г., 22:43 ч. UTC

Придобивния, сливания и поглъщания

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17.07.2025 г., 22:43 ч. UTC

Придобивния, сливания и поглъщания

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17.07.2025 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17.07.2025 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17.07.2025 г., 22:30 ч. UTC

Пазарно говорене
Печалби

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17.07.2025 г., 22:20 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

17.07.2025 г., 22:20 ч. UTC

Пазарно говорене
Печалби

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17.07.2025 г., 22:04 ч. UTC

Пазарно говорене
Печалби

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17.07.2025 г., 22:03 ч. UTC

Придобивния, сливания и поглъщания

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17.07.2025 г., 21:58 ч. UTC

Пазарно говорене
Печалби

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17.07.2025 г., 21:57 ч. UTC

Печалби

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17.07.2025 г., 21:47 ч. UTC

Печалби

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17.07.2025 г., 21:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

17.07.2025 г., 21:45 ч. UTC

Пазарно говорене

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17.07.2025 г., 21:38 ч. UTC

Придобивния, сливания и поглъщания

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17.07.2025 г., 21:22 ч. UTC

Придобивния, сливания и поглъщания

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17.07.2025 г., 21:05 ч. UTC

Печалби

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17.07.2025 г., 21:04 ч. UTC

Придобивния, сливания и поглъщания

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17.07.2025 г., 21:02 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17.07.2025 г., 20:59 ч. UTC

Придобивния, сливания и поглъщания

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17.07.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

17.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Erasca Inc Прогноза

Ценова цел

By TipRanks

200.69% нагоре

12-месечна прогноза

Среден 4.33 USD  200.69%

Висок 6 USD

Нисък 3 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Erasca Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

3

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

1.39 / 1.44Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

Very Strong Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.